Oramed Pharmaceuticals Inc

Oramed’s CEO and senior execs buy RSUs—showing insider confidence in the company’s oral insulin launch, Phase II success, and potential market‑access boost.

Oramed’s insider buying signals confidence in its oral‑insulin platform, offering a safe, effective non‑injectable therapy with strong Phase 2/3 data and upcoming FDA milestones.